AIM2 and fatty liver disease: Additionally, the nonsteroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1)/growth differentiation factor-15 (GDF15) prevents hepatic steatosis by inhibiting the activation of AIM2 (38).